Product Description
INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
Mechanisms of Action: AT1 Blocker,AT2 Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: InVasc
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypertension|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| INV144-201 | P2 |
Completed |
Type 2 Diabetes|Hypertension |
2012-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|